Numerous studies by us and others have shown the potential of sensitizing TRAIL-resistant tumor cell lines by combining TRAIL with other chemotherapeutic agents that upregulate DR4/5 levels on cells or simultaneously activate intracellular signaling cascades [12], [48]–[53]. Here, TNFRSF10A is linked to neoplasm.